New Hidradenitis Suppurativa Drug Targets Linked to Skin
Researchers have identified two specific inflammatory proteins in skin tissue that may offer new treatment targets for HS.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should biotech companies prioritize faster development of new treatments for chronic skin conditions?
At the 2026 EADV Congress, Navigator Medicines presented new data on its development program for hidradenitis suppurativa, a chronic condition affecting 1% of the global population. These findings highlight potential new therapeutic pathways for patients living with moderate-to-severe disease.
Why it matters
Hidradenitis suppurativa currently lacks sufficient treatment options for the more than one million people in the U.S. living with the condition. By targeting inflammation pathways, these new experimental therapies aim to address a significant unmet medical need for those affected.
A Phase 1 study of 64 healthy volunteers indicated a favorable safety profile and preservation of T-cell functionality for NAV-240. Researchers also identified the localization of TNFα and OX40L near draining tunnels in skin tissue, suggesting these as potential future targets.
The players
Navigator Medicines
A biotechnology company focused on developing bispecific antibody treatments for inflammatory diseases.
Johannes Griss
A researcher who presented data on the localization of inflammatory proteins within skin tissue.
The details
The experimental therapies NAV-240 and NAV-242 are bispecific antibodies designed to bind to two distinct proteins, TNFα and OX40L, simultaneously. By inhibiting both of these targets, the treatments work to reduce the inflammation associated with the skin condition. The ongoing Phase 2a MAINSAIL trial uses a multi-center, randomized, double-blind, placebo-controlled design to further assess the effectiveness of NAV-240 in patients with moderate to severe disease.
Timeline
September 30, 2026: Navigator Medicines presented new research data at the EADV Congress.
October 1, 2026: Researchers presented findings on the localization of TNFα and OX40L in skin tissue.
Third quarter 2027: Results for the NAV-240 MAINSAIL trial are expected.
Second half 2027: Full data for the NAV-242 Phase 1 study are expected.
Health Landscape
This development represents a shift toward bispecific antibodies that address multiple inflammatory pathways in complex skin conditions. It aligns with broader trends in immunology aiming to move beyond single-target therapies to improve outcomes for treatment-refractory patients.
Patients living with hidradenitis suppurativa should consult their dermatologist about whether current standard-of-care treatments remain effective for their specific symptoms. The progress of these experimental programs highlights the value of discussing emerging clinical trial opportunities with a physician.
The takeaway
Targeted therapies for inflammatory pathways represent a promising evolution in managing hidradenitis suppurativa. Patients should track symptoms and document flare patterns to provide their medical team with the most accurate data for treatment discussions.
Further reading
Learn more about the latest research and standard of care in the Cancer section.
More information
Track current updates and study locations through the Phase 2a MAINSAIL trial registry.
Source note: This article includes information reported by The Manila times.
Live Poll
Should biotech companies prioritize faster development of new treatments for chronic skin conditions?
